IMNM NASDAQ
Immunome, Inc.
1W: +4.3%
1M: -3.5%
3M: +6.8%
YTD: +10.3%
1Y: +168.2%
3Y: +302.1%
5Y: +26.6%
$21.66
-1.30 (-5.66%)
Weekly Expected Move ±4.9%
$19
$20
$21
$22
$23
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$2.1M
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.1B
52W Range7.96-27.65
Volume1,027,175
Avg Volume1,167,911
Beta2.12
Dividend—
Analyst Ratings
Company Info
CEOClay Siegall
Employees131
SectorHealthcare
IndustryBiotechnology
IPO Date2020-10-02
Websiteimmunome.com
665 Stockton Drive
Bothell, PA 19341
US
Bothell, PA 19341
US
610 321 3700
About Immunome, Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Latest News
Techne (TECH) Misses Q3 Earnings and Revenue Estimates
Exelixis (EXEL) Tops Q1 Earnings Estimates
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates
Near the top of biotech rankings, AbbVie's Q1 beat makes a case for more upside
Immunome, Inc. (NASDAQ:IMNM) Receives $33.45 Consensus PT from Analysts
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| BIENAIME JEAN JACQUE | P-Purchase | 5,000 | $20.70 | 2026-05-15 |
| Higgins Jack | S-Sale | 9,438 | $21.64 | 2026-04-02 |
| Rosett Max | S-Sale | 63,656 | $21.91 | 2026-04-02 |
| Rosett Max | S-Sale | 1,344 | $22.48 | 2026-04-02 |
| Rosett Max | M-Exempt | 39,713 | $1.35 | 2026-04-02 |